Litcius/Paper detail

Laser activatable nanographene colloids for chemo-photothermal combined gene therapy of triple-negative breast cancer

Rahul Maheshwari, Anuradha Gadeval, Nidhi Raval, Kiran Kalia, Rakesh Kumar Tekade

2021Biomaterials Advances26 citationsDOIOpen Access PDF

Abstract

This investigation reports the green approach for developing laser activatable nanoscale-graphene colloids (nGC-CO-FA) for chemo-photothermal combined gene therapy of triple-negative breast cancer (TNBC). The nano colloid was found to be nanometric as characterized by SEM, AFM, and zeta sizer (68.2 ± 2.1 nm; 13.8 ± 1.2 mV). The doxorubicin (Dox) loaded employing hydrophobic interaction/π-π stacking showed >80% entrapment efficiency with a sustained pH-dependent drug release profile. It can efficiently incorporate siRNA and Dox and successfully co-localize them inside TNBC cells to obtain significant anticancer activity as evaluated using CCK-8 assay, apoptosis assay , cell cycle analysis , cellular uptake, fluorescence assay , endosomal escape study, DNA content analysis, and gene silencing efficacy studies. nGC-CO-FA/Dox/siRNA released the Dox in temperature- and a pH-responsive manner following NIR-808 laser irradiation. The synergistic photo-chemo-gene therapy using near infrared-808 nm laser (NIR-808) irradiation was found to be more effective as compared to without NIR-808 laser-treated counterparts (∆T: 37 ± 1.1 °C → to 49.2 ± 3.1 °C; 10 min; 0.5 W/cm 2 ), suggesting the pivotal role of photothermal combined gene-therapy in the treatment of TNBC.

Topics & Concepts

Photothermal therapyTriple-negative breast cancerDoxorubicinMaterials scienceFlow cytometryCancer cellBiophysicsLaserCancerZeta potentialMolecular biologyHeLaCancer researchChemistryNanoparticleBreast cancerCellNanotechnologyBiologyBiochemistryChemotherapyGeneticsOpticsPhysicsNanoplatforms for cancer theranosticsGraphene and Nanomaterials ApplicationsNanoparticle-Based Drug Delivery
Laser activatable nanographene colloids for chemo-photothermal combined gene therapy of triple-negative breast cancer | Litcius